Such lysates may be suitable “cancer-immunotherapy enhancers” for CTLA-4 Ab, both owing to their inhibition of the growth of abnormal bacteria in CRC mice and synergy with the Toll-like receptor (TLR) signaling pathway. The gene discussed is CTLA4; the disease is colorectal carcinoma.